Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

16.80
+0.25001.51%
Post-market: 16.920.1202+0.72%17:51 EST
Volume:1.42M
Turnover:23.79M
Market Cap:2.72B
PE:-4.64
High:17.49
Open:17.09
Low:16.40
Close:16.55
52wk High:25.00
52wk Low:6.36
Shares:162.00M
Float Shares:152.00M
Volume Ratio:0.72
T/O Rate:0.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6224
EPS(LYR):-3.3716
ROE:-60.66%
ROA:-34.32%
PB:3.93
PE(LYR):-4.98

Loading ...

Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR) and Dyne Therapeutics (DYN)

TIPRANKS
·
Jan 21

Dyne Therapeutics Is Maintained at Neutral by JP Morgan

Dow Jones
·
Jan 20

Dyne announces MHLW in Japan granted ODD for zeleciment basivarsen

TIPRANKS
·
Jan 20

Japan Grants Orphan Drug Designation to Dyne Therapeutics' Zeleciment Basivarsen for Myotonic Dystrophy Type 1

Reuters
·
Jan 20

Dyne Therapeutics Inc - Achieve Trial Enrollment Expected to Complete Early Q2 2026

THOMSON REUTERS
·
Jan 20

Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (Dyne-101) for Myotonic Dystrophy Type 1

THOMSON REUTERS
·
Jan 20

U.S. RESEARCH ROUNDUP-Alphabet, Micron Technology, Microsoft

Reuters
·
Jan 20

Dyne Therapeutics Inc : JP Morgan Cuts Target Price to $16 From $17

THOMSON REUTERS
·
Jan 20

Funding for Risky Biotechs Is Returning -- WSJ

Dow Jones
·
Jan 13

Dyne Therapeutics Highlights Pipeline and Cash at JPM Conference

TIPRANKS
·
Jan 12

Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
Jan 07

BRIEF-Dyne Therapeutics Appoints Vikram Karnani To Board Of Directors

Reuters
·
Dec 23, 2025

Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

Reuters
·
Dec 23, 2025

Dyne Therapeutics Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Dec 15, 2025

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

GlobeNewswire
·
Dec 12, 2025

Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says

MT Newswires Live
·
Dec 11, 2025

Dyne Therapeutics Inc : Piper Sandler Cuts Target Price to $45 From $48

THOMSON REUTERS
·
Dec 10, 2025

Dyne Therapeutics Shares up 10%; Oppenheimer Raises to Outperform From Perform

THOMSON REUTERS
·
Dec 10, 2025

Dyne Therapeutics, Inc. : Oppenheimer Raises Target Price to $40 From $11

THOMSON REUTERS
·
Dec 10, 2025

Dyne Therapeutics, Inc. : Oppenheimer Raises to Outperform From Perform

THOMSON REUTERS
·
Dec 10, 2025